BidaskClub Downgrades AC Immune (ACIU) to Hold
AC Immune (NASDAQ:ACIU) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
Separately, Zacks Investment Research upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Monday, February 5th.
Shares of AC Immune (ACIU) opened at $11.50 on Wednesday. The stock has a market cap of $653.52 and a P/E ratio of -16.43. AC Immune has a 12 month low of $6.03 and a 12 month high of $13.91.
Large investors have recently modified their holdings of the stock. Belpointe Asset Management LLC bought a new stake in shares of AC Immune in the third quarter worth $571,000. Wells Fargo & Company MN acquired a new position in AC Immune in the third quarter worth $111,000. Janney Montgomery Scott LLC acquired a new position in AC Immune in the third quarter worth $134,000. Goldman Sachs Group Inc. acquired a new position in AC Immune in the second quarter worth $127,000. Finally, Renaissance Technologies LLC acquired a new position in AC Immune in the fourth quarter worth $143,000. Institutional investors and hedge funds own 17.12% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://theolympiareport.com/2018/02/14/bidaskclub-downgrades-ac-immune-aciu-to-hold.html.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.